Compounds > 3-hydroxyquinolin-2(1h)-one
Page last updated: 2024-11-09

3-hydroxyquinolin-2(1h)-one

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-hydroxyquinolin-2(1H)-one: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

dihydroxyquinoline : Any hydroxyquinoline in which the number of hydroxy substituents is specified as two. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID818159
CHEMBL ID146227
CHEBI ID167880
SCHEMBL ID209889
MeSH IDM0588719

Synonyms (27)

Synonym
quinolinediol
CHEBI:167880
3-hydroxy-1h-quinolin-2-one
g3e ,
3-hydroxyquinolin-2(1h)-one
CHEMBL146227
AKOS000265873
bdbm31148
3-hydroxyquinolin-2(1h)-one, 2
2,3-quinolinediol ,
26386-86-7
STK249667
quinoline-2,3-diol
AKOS006241939
SCHEMBL209889
hydroxyquinolone
dihydroxyquinoline
2,3-dihydroxyquinoline
mfcd08705722
DTXSID70355913
FT-0717924
Q27460539
AS-38602
3-hydroxycarbostyril
SB67760
BBA38686
SY241254
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
quinolone
hydroxyquinoline
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
D-amino-acid oxidaseRattus norvegicus (Norway rat)IC50 (µMol)0.27660.00400.25890.8550AID1300692; AID1799106; AID371709
D-amino-acid oxidaseHomo sapiens (human)IC50 (µMol)0.16710.00401.119910.0000AID1300693; AID1799106; AID371707; AID735284; AID735291
Reverse transcriptase/RNaseH Human immunodeficiency virus 1IC50 (µMol)100.00000.00011.076810.0000AID662969
D-aspartate oxidaseHomo sapiens (human)IC50 (µMol)0.48230.00400.39370.8550AID1799106; AID371708
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
D-amino-acid oxidaseSus scrofa (pig)Kd0.15000.15002.81006.3000AID1389535
D-amino-acid oxidaseHomo sapiens (human)Kd0.01300.00311.72789.0000AID1799107; AID371729
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (14)

Processvia Protein(s)Taxonomy
proline catabolic processD-amino-acid oxidaseHomo sapiens (human)
digestionD-amino-acid oxidaseHomo sapiens (human)
D-amino acid catabolic processD-amino-acid oxidaseHomo sapiens (human)
D-serine catabolic processD-amino-acid oxidaseHomo sapiens (human)
dopamine biosynthetic processD-amino-acid oxidaseHomo sapiens (human)
D-alanine catabolic processD-amino-acid oxidaseHomo sapiens (human)
D-serine metabolic processD-amino-acid oxidaseHomo sapiens (human)
neutrophil-mediated killing of gram-negative bacteriumD-amino-acid oxidaseHomo sapiens (human)
inseminationD-aspartate oxidaseHomo sapiens (human)
grooming behaviorD-aspartate oxidaseHomo sapiens (human)
regulation of cell communicationD-aspartate oxidaseHomo sapiens (human)
D-amino acid catabolic processD-aspartate oxidaseHomo sapiens (human)
hormone metabolic processD-aspartate oxidaseHomo sapiens (human)
nervous system processD-aspartate oxidaseHomo sapiens (human)
aspartate catabolic processD-aspartate oxidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
D-amino-acid oxidase activityD-amino-acid oxidaseHomo sapiens (human)
protein bindingD-amino-acid oxidaseHomo sapiens (human)
identical protein bindingD-amino-acid oxidaseHomo sapiens (human)
FAD bindingD-amino-acid oxidaseHomo sapiens (human)
protein bindingD-aspartate oxidaseHomo sapiens (human)
D-aspartate oxidase activityD-aspartate oxidaseHomo sapiens (human)
D-glutamate oxidase activityD-aspartate oxidaseHomo sapiens (human)
FAD bindingD-aspartate oxidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
mitochondrial outer membraneD-amino-acid oxidaseHomo sapiens (human)
extracellular regionD-amino-acid oxidaseHomo sapiens (human)
cytoplasmD-amino-acid oxidaseHomo sapiens (human)
peroxisomal matrixD-amino-acid oxidaseHomo sapiens (human)
cytosolD-amino-acid oxidaseHomo sapiens (human)
cell projectionD-amino-acid oxidaseHomo sapiens (human)
presynaptic active zoneD-amino-acid oxidaseHomo sapiens (human)
cytoplasmD-amino-acid oxidaseHomo sapiens (human)
peroxisomeD-aspartate oxidaseHomo sapiens (human)
peroxisomeD-aspartate oxidaseHomo sapiens (human)
peroxisomal matrixD-aspartate oxidaseHomo sapiens (human)
cytosolD-aspartate oxidaseHomo sapiens (human)
cytoplasmD-aspartate oxidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (44)

Assay IDTitleYearJournalArticle
AID662976Selectivity ratio of IC50 for HIV1 reverse transcriptase associated RNA dependent polymerase activity to IC50 for reverse transcriptase Rnase H activity2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Development of a series of 3-hydroxyquinolin-2(1H)-ones as selective inhibitors of HIV-1 reverse transcriptase associated RNase H activity.
AID371717Ratio of drug level in brain to plasma in Sprague-Dawley CD rat at 56 mg/kg, sc after 4 hrs2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.
AID371730Dissociation constant, pKa of the compound2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.
AID1171397Drug metabolism in mouse liver microsomes assessed as glucuronidation of compound measured as compound remaining after 30 mins by LC/MS analysis2014ACS medicinal chemistry letters, Nov-13, Volume: 5, Issue:11
Structure-Metabolism Relationships in the Glucuronidation of d-Amino Acid Oxidase Inhibitors.
AID1300692Inhibition of rat spinal DAAO using D-alanine as substrate assessed as pyruvate production incubated for 60 mins by microplate reader analysis2016European journal of medicinal chemistry, Jul-19, Volume: 117Discovery and analgesic evaluation of 8-chloro-1,4-dihydropyrido[2,3-b]pyrazine-2,3-dione as a novel potent d-amino acid oxidase inhibitor.
AID735291Inhibition of human recombinant DAAO after 30 mins by plate reader analysis2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
4-Hydroxypyridazin-3(2H)-one derivatives as novel D-amino acid oxidase inhibitors.
AID371727Ratio of drug level in brain to plasma in Sprague-Dawley CD rat at 10 mg/kg, sc after 4 hrs2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.
AID371714Cmax in Sprague-Dawley CD rat at 3 mg/kg, po2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.
AID371722Fraction unbound in Sprague-Dawley CD rat plasma at 10 mg/kg, sc after 4 hrs2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.
AID662969Inhibition of HIV1 reverse transcriptase RNase H activity2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Development of a series of 3-hydroxyquinolin-2(1H)-ones as selective inhibitors of HIV-1 reverse transcriptase associated RNase H activity.
AID371726Free drug level in Sprague-Dawley CD rat brain at 10 mg/kg, sc after 4 hrs2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.
AID371713Oral bioavailability in Sprague-Dawley CD rat at 3 mg/kg2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.
AID735284Inhibition of DAAO (unknown origin) by cell based assay2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
4-Hydroxypyridazin-3(2H)-one derivatives as novel D-amino acid oxidase inhibitors.
AID371709Inhibition of rat recombinant DAAO expressed in sf9 insect cells assessed as degradation of D-serine by fluorescence assay2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.
AID371720Displacement of [3H]glycine from NMDA receptor at 10 uM2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.
AID371725Fraction unbound in Sprague-Dawley CD rat brain at 10 mg/kg, sc after 4 hrs2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.
AID662977Selectivity ratio of IC50 for HIV1 integrase to IC50 for reverse transcriptase Rnase H activity2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Development of a series of 3-hydroxyquinolin-2(1H)-ones as selective inhibitors of HIV-1 reverse transcriptase associated RNase H activity.
AID1171400Drug metabolism in mouse liver microsomes assessed as glucuronidation of compound measured as compound remaining after 60 mins by LC/MS analysis2014ACS medicinal chemistry letters, Nov-13, Volume: 5, Issue:11
Structure-Metabolism Relationships in the Glucuronidation of d-Amino Acid Oxidase Inhibitors.
AID735290Effective permeability of the compound at pH 6.5 after 2 hrs by PAMPA2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
4-Hydroxypyridazin-3(2H)-one derivatives as novel D-amino acid oxidase inhibitors.
AID371728Selectivity ratio of IC50 for rat DAAO to IC50 for human DAAO2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.
AID371723Free plasma concentration in Sprague-Dawley CD rat at 10 mg/kg, sc after 4 hrs2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.
AID1300693Inhibition of human recombinant DAAO using D-alanine as substrate assessed as pyruvate production incubated for 60 mins by microplate reader analysis2016European journal of medicinal chemistry, Jul-19, Volume: 117Discovery and analgesic evaluation of 8-chloro-1,4-dihydropyrido[2,3-b]pyrazine-2,3-dione as a novel potent d-amino acid oxidase inhibitor.
AID1389535Binding affinity to pig kidney DAAO by ITC method2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Discovery of isatin and 1H-indazol-3-ol derivatives as d-amino acid oxidase (DAAO) inhibitors.
AID371707Inhibition of human recombinant DAAO expressed in sf9 insect cells assessed as degradation of D-serine by fluorescence assay2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.
AID371708Inhibition of human recombinant DDO expressed in sf9 insect cells assessed as degradation of D-serine by fluorescence assay2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.
AID662972Cytotoxicity against human MT4 cells2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Development of a series of 3-hydroxyquinolin-2(1H)-ones as selective inhibitors of HIV-1 reverse transcriptase associated RNase H activity.
AID371719Free drug level in Sprague-Dawley CD rat brain at 56 mg/kg, sc after 4 hrs2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.
AID1300691Inhibition of DAAO in porcine kidney homogenate using D-alanine as substrate assessed as pyruvate production incubated for 5 mins by microplate reader analysis2016European journal of medicinal chemistry, Jul-19, Volume: 117Discovery and analgesic evaluation of 8-chloro-1,4-dihydropyrido[2,3-b]pyrazine-2,3-dione as a novel potent d-amino acid oxidase inhibitor.
AID371718Fraction unbound in Sprague-Dawley CD rat brain at 56 mg/kg, sc after 4 hrs2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.
AID662971Antiviral activity against HIV1 infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Development of a series of 3-hydroxyquinolin-2(1H)-ones as selective inhibitors of HIV-1 reverse transcriptase associated RNase H activity.
AID371710Clearance in Sprague-Dawley CD rat plasma at 3 mg/kg, po and 1 mg/kg, iv2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.
AID371712Half life in Sprague-Dawley CD rat at 3 mg/kg, po and 1 mg/kg, iv2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.
AID371724Drug level in Sprague-Dawley CD rat brain at 10 mg/kg, sc after 4 hrs2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.
AID371716Elevation of D-serine level in Sprague-Dawley CD rat cerebellum at 56 mg/kg, sc by LC/MS-MS analysis relative to control2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.
AID371732Efflux ratio of permeability from apical to basolateral over basolateral to apical side in human MDR1 transfected MDCK cells2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.
AID371715Elevation of D-serine level in sc dosed Sprague-Dawley CD rat cerebellum by LC/MS-MS analysis2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.
AID371711Volume of distribution in Sprague-Dawley CD rat at 3 mg/kg, po and 1 mg/kg, iv2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.
AID371733Ratio of free drug level in Sprague-Dawley CD rat brain to IC50 for rat DAAO activity2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.
AID371721Plasma concentration in Sprague-Dawley CD rat at 10 mg/kg, sc after 4 hrs2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.
AID371729Binding affinity to biotinylated human recombinant DAAO by Biacore assay2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.
AID662970Inhibition of HIV1 reverse transcriptase RNase H activity assessed as remaining activity at 100 uM2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Development of a series of 3-hydroxyquinolin-2(1H)-ones as selective inhibitors of HIV-1 reverse transcriptase associated RNase H activity.
AID748668Inhibition of H1N1 Influenza A endonuclease after 1 hr by fluorescence assay2013ACS medicinal chemistry letters, Jun-13, Volume: 4, Issue:6
3-Hydroxyquinolin-2(1H)-ones As Inhibitors of Influenza A Endonuclease.
AID1799106DAAO in Vitro Activity Assay from Article 10.1021/jm900128w: \\Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.\\2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.
AID1799107Biacore Binding of DAAO Inhibitors from Article 10.1021/jm900128w: \\Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.\\2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's7 (77.78)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.15 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index5.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
benzoic acid
Benzoic Acid: A fungistatic compound that is widely used as a food preservative. It is conjugated to GLYCINE in the liver and excreted as hippuric acid.. benzoic acid : A compound comprising a benzene ring core carrying a carboxylic acid substituent.. aromatic carboxylic acid : Any carboxylic acid in which the carboxy group is directly bonded to an aromatic ring.		2.0510benzoic acidsalgal metabolite;
antimicrobial food preservative;
drug allergen;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor;
human xenobiotic metabolite;
plant metabolite
sulfuric acid
sulfuric acid : A sulfur oxoacid that consists of two oxo and two hydroxy groups joined covalently to a central sulfur atom.		2.0810sulfur oxoacidcatalyst
gaboxadol
gaboxadol: GABA agonist; inhibitor of GABA uptake systems; structure		2.1710oxazole
carbostyril
Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.		2.5520monohydroxyquinoline;
quinolone		bacterial xenobiotic metabolite
benzoxazolone
benzoxazolone: RN given refers to parent cpd; structure. 2-benzoxazolinone : A member of the class of benzoxazoles that is 2,3-dihydro-1,3-benzoxazole carrying an oxo group at position 2.		2.1710benzoxazoleallelochemical;
phytoalexin
phenylalanine
Phenylalanine: An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.. L-phenylalanine : The L-enantiomer of phenylalanine.. phenylalanine : An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group.		7.3110amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
phenylalanine;
proteinogenic amino acid		algal metabolite;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
Escherichia coli metabolite;
human xenobiotic metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
trifluoroacetic acid
Trifluoroacetic Acid: A very strong halogenated derivative of acetic acid. It is used in acid catalyzed reactions, especially those where an ester is cleaved in peptide synthesis.. trifluoroacetic acid : A monocarboxylic acid that is the trifluoro derivative of acetic acid.		2.0810fluoroalkanoic acidhuman xenobiotic metabolite;
NMR chemical shift reference compound;
reagent
isatin
tribulin: endogenous MONOAMINE OXIDASE inhibitory activity extractable into ethyl acetate found in brain and many mammalian tissues and fluids; ISATIN is a major component; produced in excess following alcohol withdrawal;		2.1710indoledioneEC 1.4.3.4 (monoamine oxidase) inhibitor;
plant metabolite
acetoacetanilide
N-phenylacetoacetamide: structure in first source		2.0810
2-aminobenzothiazole
[no description available]		2.1710benzothiazoles
5-methylpyrazole-3-carboxylic acid
5-methylpyrazole-3-carboxylic acid: structure. 5-methyl-pyrazole-3-carboxylic acid : A memebr of the class of pyrazoles that is 1H-pyrazole with methyl and carboxylic acid group substituents at positions 5 and 3 respectively.		2.4720monocarboxylic acid;
pyrazoles		metabolite
2-hydroxy benzimidazole
2-hydroxy benzimidazole: structure in first source		2.1710
3-hydroxy-1-benzopyran-2-one
3-hydroxycoumarin: Photoprotective from sea urchin gametes and embryonic cells; structure in first source. hydroxycoumarin : Any coumarin carrying at least one hydroxy substituent.		2.110hydroxycoumarin
2,3-dihydroxyquinoxaline
2,3-dihydroxyquinoxaline: fluorescent oxalic acid deriv.		2.1310
2,3-dihydroxypyridine
2,3-dihydroxypyridine: affects thyroid function. pyridine-2,3-diol : A dihydroxypyridine in which the two hydroxy groups are located at positions 2 and 3.		2.0810dihydroxypyridine
viridicatin
viridicatin: structure. viridicatin : A hydroxyquinolone that is 3-hydroxyuinolin-2(1H)-one which is substituted at position 4 by a phenyl groups. Isolated from the mycelium of several Penicillium species, it exhibits strong antibiotic activity against M. tuberculosis and also against B. subtilis, S. aureus and S. cerevisiae.		2.0810hydroxyquinolineantibacterial agent;
Aspergillus metabolite;
marine metabolite;
Penicillium metabolite
3-indazolinone
3-indazolinone: structure given in first source		2.1710
5-Chloro-1H-indole-2,3-dione
[no description available]		2.1710indolesanticoronaviral agent
bis(i,i-trifluoroacetoxy)iodobenzene
phenyliodine(III) bis(trifluoroacetate): structure in first source		2.0810
dizocilpine
[no description available]		2.1310secondary amino compound;
tetracyclic antidepressant		anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist
5-Fluoroisatin
[no description available]		2.1710indolesanticoronaviral agent
2-mercaptobenzimidazole
2-mercaptobenzimidazole: purine synthesis antimetabolite; RN given refers to parent cpd		2.1710
6-Chlorobenzo[d]isoxazol-3-ol
[no description available]		3.0240benzisoxazole
6-(1-(4-fluorophenyl)methyl-1h-pyrrol-2-yl)-2,4-dioxo-5-hexenoic acid ethyl ester
[no description available]		2.0710
sun
[no description available]		2.0510
ConditionIndicatedRelationship StrengthStudiesTrials
Diseases, Metabolic
[description not available]		02.3110
BH4 Deficiency
[description not available]		02.3110
Metabolic Diseases
Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)		02.3110
Phenylketonurias
A group of autosomal recessive disorders marked by a deficiency of the hepatic enzyme PHENYLALANINE HYDROXYLASE or less frequently by reduced activity of DIHYDROPTERIDINE REDUCTASE (i.e., atypical phenylketonuria). Classical phenylketonuria is caused by a severe deficiency of phenylalanine hydroxylase and presents in infancy with developmental delay; SEIZURES; skin HYPOPIGMENTATION; ECZEMA; and demyelination in the central nervous system. (From Adams et al., Principles of Neurology, 6th ed, p952).		02.3110